Microparticles comprising moxidectin, and preparation method therefor

A moxidectin and microparticle technology, applied in the field of moxidectin and biodegradable polymer microparticles and its preparation, can solve the problems of exposure to infection, forgetting to take the number of times, etc., to reduce foreign body sensation and pain, injection The effect of easy administration

Pending Publication Date: 2019-10-25
INVENTAGE LAB INC
View PDF12 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

When taken correctly, preventive medicines are excellent in their preventive effects, but since they need to be taken daily or monthly, there is a possibility of forgetting the number of times to take them, which may lead to the risk of exposure to infection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Microparticles comprising moxidectin, and preparation method therefor
  • Microparticles comprising moxidectin, and preparation method therefor
  • Microparticles comprising moxidectin, and preparation method therefor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0079] Poly(lactic-co-glycolic acid) (PLGA) and moxidectin were dissolved in dichloromethane to prepare a first mixture. At this time, the poly(lactic-co-glycolic acid) copolymer in the first mixture was included at a ratio of 15% by weight, and the weight ratio of the poly(lactic-co-glycolic acid) copolymer and moxidectin was 9:1.

[0080] Polyvinyl alcohol as a surfactant was mixed with water to prepare a second mixture containing 0.25% by weight of polyvinyl alcohol.

[0081] The first mixture and the second mixture are injected into the microchannels formed on the silicon wafer and allowed to flow. At this time, in order to make the first mixture and the second mixture flow at constant flow rates, the first mixture was made to flow under a pressure condition of 1000 mbar, and the second mixture was made to flow under a pressure condition of 2000 mbar. The temperature condition was maintained at 17°C.

[0082] The particulates generated at the point of intersection where ...

Embodiment 2

[0085] It was prepared in the same manner as in Example 1, except that the weight ratio of poly(lactic-co-glycolic acid) and moxidectin was 4:1.

Embodiment 3

[0087] It was prepared in the same manner as in Example 1 except that the weight ratio of poly(lactic-co-glycolic acid-co-glycolic acid) and moxidectin was 2:1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
particle sizeaaaaaaaaaa
Login to view more

Abstract

The present invention relates to microparticles comprising moxidectin and a biodegradable polymer, wherein the microparticles comprising moxidectin have a shape allowing a moxidectin drug to be uniformly distributed in spherical biodegradable polymer particles, and the average particle diameter of the microparticles is 80-130 microns. The present invention relates to: extended release microparticles capable of continuously maintaining a heartworm disease prevention effect for 3-6 months by administering microparticles comprising moxidectin; and a preparation method therefor. In addition, the present invention is prepared such that the average diameters of the particles have a predetermined micrometer size, and thus reduces a foreign body sensation and pain during administration into an animal through injection, thereby enabling administration through injection to be facilitated.

Description

technical field [0001] The present invention relates to a microparticle containing moxidectin and a preparation method thereof, more specifically, to a microparticle containing moxidectin capable of preventing heartworm and a biodegradable polymer and its preparation method. Background technique [0002] Heartworm Disease (HWD) is a mosquito-borne parasite called Dirofilaria immitis that infects dogs, cats and weasels. As the name suggests, heartworms live in the hearts of mammals. [0003] Heartworm adult worms can grow to 30cm, mainly in the pulmonary artery and right ventricle. Mature female and male heartworms produce very small larvae called microfilariae (L1). The larvae live in the blood of infected animals and infect other animals through mosquitoes. The L1 that enters the mosquito body will become infectious after two weeks, and the infectious larvae will be transmitted to other animals through mosquitoes again. Larvae that infect other animals migrate to the p...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/16A61K31/365A61K47/34A61P33/10
CPCA61K31/365A61K9/1647A61K9/0019A61K9/146A61K47/34A61K31/352
Inventor 金株希
Owner INVENTAGE LAB INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap